BioCryst Pharmaceuticals (BCRX) formed a seven-member Scientific Advisory Board to guide its research & development strategy and help expand its rare disease pipeline, the company said Monday.

The board will advise on pipeline expansion, external innovation opportunities, translational science, clinical development and regulatory strategy, the company said.

BioCryst Pharmaceuticals shares were up 1.4% in premarket activity.